Search Results - "Turaj, Anna H."

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study by Lim, Sean H, Stuart, Beth, Joseph-Pietras, Debora, Johnson, Marina, Campbell, Nicola, Kelly, Adam, Jeffrey, Danielle, Turaj, Anna H, Rolfvondenbaumen, Kate, Galloway, Celine, Wynn, Thomas, Coleman, Adam R, Ward, Benjamin, Long, Karen, Coleman, Helen, Mundy, Carina, Bates, Andrew T, Ayres, Diana, Lown, Robert, Falconer, Janlyn, Brake, Oliver, Batchelor, James, Willimott, Victoria, Bowzyk Al-Naeeb, Anna, Robinson, Lisa, O'Callaghan, Ann, Collins, Graham P, Menne, Tobias, Faust, Saul N, Fox, Christopher P, Ahearne, Matthew, Johnson, Peter W M, Davies, Andrew J, Goldblatt, David

“…Patients with hematological malignancies are at increased risk of severe COVID-19 outcomes due to compromised immune responses, but the insights of these…”
Get full text

Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering by Heckel, Franziska, Turaj, Anna H., Fisher, Hayden, Chan, H. T. Claude, Marshall, Michael J. E., Dadas, Osman, Penfold, Christine A., Inzhelevskaya, Tatyana, Mockridge, C. Ian, Alvarado, Diego, Tews, Ivo, Keler, Tibor, Beers, Stephen A., Cragg, Mark S., Lim, Sean H.

“…Agonistic CD27 monoclonal antibodies (mAb) have demonstrated impressive anti-tumour efficacy in multiple preclinical models but modest clinical responses. This…”
Get full text

Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment by Turaj, Anna H., Hussain, Khiyam, Cox, Kerry L., Rose-Zerilli, Matthew J.J., Testa, James, Dahal, Lekh N., Chan, H.T. Claude, James, Sonya, Field, Vikki L., Carter, Matthew J., Kim, Hyung J., West, Jonathan J., Thomas, Lawrence J., He, Li-Zhen, Keler, Tibor, Johnson, Peter W.M., Al-Shamkhani, Aymen, Thirdborough, Stephen M., Beers, Stephen A., Cragg, Mark S., Glennie, Martin J., Lim, Sean H.

“…Monoclonal antibodies (mAbs) can destroy tumors by recruiting effectors such as myeloid cells, or targeting immunomodulatory receptors to promote cytotoxic…”
Get full text

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking by Turaj, Anna H., Cox, Kerry L., Penfold, Christine A., French, Ruth R., Mockridge, C. Ian, Willoughby, Jane E., Tutt, Alison L., Griffiths, Jordana, Johnson, Peter W. M., Glennie, Martin J., Levy, Ronald, Cragg, Mark S., Lim, Sean H.

“…CD134 (OX40) is a member of the tumour necrosis factor receptor superfamily (TNFRSF). It acts as a costimulatory receptor on T cells, but its role on NK cells…”
Get full text

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo by Palazzo, Adam, Herter, Sylvia, Grosmaire, Laura, Jones, Randy, Frey, Christian R, Limani, Florian, Bacac, Marina, Umana, Pablo, Oldham, Robert J, Marshall, Michael J E, Cox, Kerry L, Turaj, Anna H, Cragg, Mark S, Klein, Christian, Carter, Matthew J, Tannheimer, Stacey

“…Idelalisib is a highly selective oral inhibitor of PI3Kδ indicated for the treatment of patients with relapsed chronic lymphocytic leukemia in combination with…”
Get full text

TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter by Turaj, Anna H, Dahal, Lekh N, Beers, Stephen A, Cragg, Mark S, Lim, Sean H

Get full text

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression by Cummin, ThomasE.C., Cox, Kerry L., Murray, Tom D., Turaj, Anna H., Dunning, Lisa, English, Vikki L., Fell, Rachel, Packham, Graham, Ma, Yan, Powell, Ben, Johnson, PeterW.M., Cragg, Mark S., Carter, Matthew J.

“…Although the MYC oncogenic network represents an attractive therapeutic target for lymphoma, MYC inhibitors have been difficult to develop. Alternatively,…”
Get full text

PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis by Carter, Matthew J, Cox, Kerry L, Blakemore, Stuart J, Turaj, Anna H, Oldham, Robert J, Dahal, Lekh N., Tannheimer, Stacey, Forconi, Francesco, Packham, Graham, Cragg, Mark S

“…Introduction: Phosphatidylinositol-3-kinase δ (PI3Kδ)-signaling provides key maintenance, proliferation, and survival cues during both normal and malignant…”
Get full text

Anti-CD27 Enhances Lymphoma Immunotherapy through Profound Myeloid Cell Recruitment by Turaj, Anna H, Field, Vikki L, Chan, Claude H.T., Penfold, Christine A., Kim, Jinny H., James, Sonya, Cox, Kerry L, Keler, Tibor, Johnson, Peter M, Al-Shamkhani, Aymen, Beers, Stephen A, Glennie, Martin J., Cragg, Mark S, Lim, Sean H

“…Direct-targeting monoclonal antibodies (mAb) such as anti-CD20 mAb are thought to elicit their anti-tumor function through antibody-dependent cellular…”
Get full text